SAN DIEGO — Taiwan-based WCC Biomedical is making its U.S. brand debut at the NACDS Total Store Expo, introducing its WINMAP microarray patch (MAP) technology and unveiling new products designed for both pharmaceutical and supplement applications. Chain Drug Review spoke to company representatives Ching Chen Tseng and Chin Chia-Liu on the TSE floor.
Founded 11 years ago, the company specializes in developing and mass-manufacturing microneedle patches, a critical step in commercialization. “For micro patch developers, the ability to manufacture is key to bringing innovations to market,” Tseng explained. WCC’s product pipeline includes pharmaceutical patches for pain relief, as well as wellness-focused offerings such as herbal and supplement delivery patches that enhance local ingredient concentration without the need for injections.
While WCC has previously partnered with global firms as a contract developer and CDMO, this marks the first time it is presenting its own brand at a U.S. trade show. At the event’s retailer-buyer meetings, Meet the Market, the company met with 30 prospective partners.
Meet the Market
“They were all very interested in our product,” Tseng said. “The next steps include starting with e-commerce channels and securing FDA and Canadian approvals.”
WCC’s WINMAP platform, which supports scalable manufacturing of more than 10 million MAPs annually, enables painless, needle-free delivery of active ingredients. The company holds fourteen international patents and continues to pursue expansion, with an IPO planned for 2027. Beyond the commercial market, WCC views the technology to enhance health equity in low-resource settings where injection-based therapies are challenging to administer.
More information is available at wccbiomedical.com.
